Prostate Cancer Screening in Men With Germline BRCA2 Mutations



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:30 - 90
Updated:1/11/2018
Start Date:May 2014
End Date:May 2018

Use our guide to learn which trials are right for you!

The purpose of this study is to determine the incidence of prostate cancer in men with the
BRCa2 gene mutation as an independent indicator for prostate cancer screening.

This is a cohort screening study to prospectively identify the incidence of prostate cancer
in a population of BRCA2 carriers. All men identified to have a BRCA2 mutation as part of the
Yale Cancer Genetic Counseling Program will be approached and offered participation in the
study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing.

Standard of care screening at the Yale Cancer Center for men with a normal prostate cancer
risk consists of a PSA test and prostate physical examination beginning at age 50 years and
if either is abnormal an MRI of the prostate followed by Fusion-targeted biopsy of the
prostate is performed.

Inclusion Criteria:

- All men ≥30 years of age with at least a ten-year life expectancy

- A known BRCA2 mutation

- Ability to have an MRI

- Able to give informed consent will be approached to participate in the study

Exclusion Criteria:

- If a man has received or is currently receiving treatment for prostate cancer
We found this trial at
1
site
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Preston Sprenkle, MD
Phone: 203-785-2052
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials